Clinical evaluation of sintilimab in conjunction with bevacizumab for advanced colorectal cancer with microsatellite stable-type after failure of first-line therapy

Figure 1 Comparison of the positive expression rates of cluster of differentiation 8 (+) T lymphocytes, tumor-associated macrophages, and cancer-associated fibroblasts before and after treatment in two groups of patients. The percentages of tumor-associated macrophages and cancer-associated fibroblasts in the experimental group were significantly lower after treatment than those before treatment. CD: Cluster of differentiation; TAMs: Tumor-associated macrophages; CAFs: Cancer-associated fibroblasts.

Figure 2 Comparison of short-term survival stations between the two groups. The progression-free survival of the experimental participants was markedly prolonged relative to the controls. PFS: Progression-free survival.

Figure 3 Comparison of drug-related adverse reactions in the two groups of patients. The incidence of adverse events insignificantly differed between experimental participants and controls.